Evolent has more than 1,400 clinicians—including 300 physicians—focused on improving health outcomes for cancer, cardiovascular disease, musculoskeletal conditions and more. Watch to learn how our evidence-driven, patient-first model helps produce more informed treatment decisions.
Other content in this Stream
![AI-curated clinical pathways? Not so fast.](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-552376%2Fimage%2Fupload%2Fv1721402349%2FEV-2312633-Rebrand_Uberflip-Icon_Tile-AI_asim3y.jpg&size=1&version=1721835305&sig=a180102433e470b2ff85ee49cc247b33&default=hubs%2Ftilebg-blogs.jpg)
Could generative AI replace expert consensus for devising clinical guidelines? Our chief medical officer takes a look.
![Value-based strategies for connecting primary and specialty care](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-552376%2Fimage%2Fupload%2Fv1710966113%2Fitemeditorimage_65ddf92b92aac-1908117.jpg&size=1&version=1721667187&sig=6439a562692becab725e5940da339674&default=hubs%2Ftilebg-blogs.jpg)
To reduce the fragmentation of care for complex conditions, we need to take on the fee-for-service models that contribute to it, says Evolent’s Dr. Vishnukamal Golla.
![Another Toxicity of Cancer Treatment](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZGRmZmQ1NTg5NDAuanBnJnZlcnNpb249MDAwMCZzaWc9NjQwMjVjYTU2ZGRhYzJhMmNlYmFhMTY0ODAzN2ZhMGI%25253D&size=1&version=1721156286&sig=767be6c306ed6c3a1b2b3641597762c9&default=hubs%2Ftilebg-blogs.jpg)
Cancer treatment and the time spent traveling for care are often very time-consuming. By recognizing and working to decrease time toxicity for patients with cancer, we can lessen their burden.
![Dr. Sadie Dobrozsi Discusses the Future of Genetic Testing in Oncology and the Impact on Women’s Health](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZGRmOTJiOTJhYWMuanBnJnZlcnNpb249MDAwMCZzaWc9YWM0Y2FhMmYyMzQ5ZTIwOWNmNzQwMDY3OGI3MDRkODU%25253D&size=1&version=1721141646&sig=48eb04974f2920b0ab3a4638a6f1b4c8&default=hubs%2Ftilebg-blogs.jpg)
A stronger, unified voice in our scientific community will impact the accessibility of genetic testing so that it becomes standard preventive care for everyone who qualifies — and who wants it.
![Evolent to acquire AI utilization management products and team from Machinify](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-552376%2Fimage%2Fupload%2Fv1718215688%2FEV_2412703_2024_Uberflip_Requests_machinify_0612_zjp508.jpg&size=1&version=1718215879&sig=b7b69e5c26098c4457927cbb96ef5c7e&default=hubs%2Ftilebg-blogs.jpg)
Addition will help Evolent to increase first-pass approvals and streamline data collection in complex medical decision making.
![Evolent and Careology form strategic care navigation partnership](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY0YzE4ZWM4YTk1MDUuanBnJnZlcnNpb249MDAwMCZzaWc9YTVhYjZhOGI5NmUzNmFiNzUzYjdkMDk2NWQzNGI5ZTk%25253D&size=1&version=1715346371&sig=c466deaabc6d86071561f42cf347c803&default=hubs%2Ftilebg-blogs.jpg)
Joint offering will seek to to enable more coordinated, connected and empowered journeys for people living with cancer in the U.S.
![True peer-to-peer conversations will improve prior authorization](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MzRmMWM2NjhlZDIuanBnJnZlcnNpb249MDAwMCZzaWc9MDQ1ZTQ1NjVlMTU5MmIwYWM2N2Q1YjBjMzZkYTI5ZmI%25253D&size=1&version=1714745809&sig=c2d3403277b9b501405400cafdbca595&default=hubs%2Ftilebg-blogs.jpg)
Dr. Matthew Walker writes in STAT about one big step to make peer conversations more collegial and productive.
![The “dystopian” state of primary care](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fembed-ssl.wistia.com%2Fdeliveries%2Fef3851865ee771d24ab829e49068ccaa10d03908.jpg&size=1&version=1715348883&sig=bbd0d0abd1caef2d5229c4c259c3c0d2&default=hubs%2Ftilebg-videos.jpg)
Evolent's Dr. Kamal Golla speaks with the Healthcare Finance Management Association’s Voices podcast about the challenges of connecting primary and specialty care.
![Evolent Announces Focus on Specialty Care With Rebrand, Unification of Solutions](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MDViNGUwMjVmZjEuanBnJnZlcnNpb249MDAwMCZzaWc9NTgwNzBkYWM0NjY0OTgyMmVhODExMWMxMmRhMTgyMWE%25253D&size=1&version=1711657335&sig=038dc2f65f7d980e7eb25a5ab6d94ce8&default=hubs%2Ftilebg-blogs.jpg)
Company's solutions are coming together to improve outcomes for people living with complex health conditions.
![It's Cancer Prevention Month. Here are 11 ways to reduce your risk.](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZTBmNTVkYzhmODMucG5nJnZlcnNpb249MDAwMCZzaWc9OTc2MzE3YTU5YTJiOTNjZjdjZDM0YWE4ODRhYmVhM2M%25253D&size=1&version=1709242806&sig=965de2535a149e580a8cf0b8a3532292&default=hubs%2Ftilebg-blogs.jpg)
Our CMO, Dr. Andrew Hertler, talks to Yahoo Life about identifying which patients need genetic testing or aggressive cancer screening, the issues surrounding prophylactic surgery, and more.
![Trends clinical leaders, hospital execs say will shape healthcare beyond 2024](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY0ZGFjYjljMTAwODEuanBnJnZlcnNpb249MDAwMCZzaWc9OGRhOGNkM2MyMjE2NDZkODY3MmFiMzYyNzYzNjBlYTM%25253D&size=1&version=1708720991&sig=aae6067a61ed11859aa6e4a428e01546&default=hubs%2Ftilebg-blogs.jpg)
Becker's highlights our CMO's predictions on the future of health care.
![Prophylactic Mastectomy for Patients With High-Risk Gene Mutations](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY0ZGFjYjljMTAwODEuanBnJnZlcnNpb249MDAwMCZzaWc9OGRhOGNkM2MyMjE2NDZkODY3MmFiMzYyNzYzNjBlYTM%25253D&size=1&version=1709053589&sig=fa2486050447290dfb353b4a5077284e&default=hubs%2Ftilebg-blogs.jpg)
Dr. Andrew Hertler discussed the importance of prophylactic mastectomy for individuals carrying BRCA1, BRCA2 and other deleterious mutations.
![Medicare Drug Price Negotiations and Anticipated Ripple Effects](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZGRmZmQ1NTg5NDAuanBnJnZlcnNpb249MDAwMCZzaWc9NjQwMjVjYTU2ZGRhYzJhMmNlYmFhMTY0ODAzN2ZhMGI%25253D&size=1&version=1709047766&sig=f0f596b93b0422216321cd333df9a855&default=hubs%2Ftilebg-blogs.jpg)
Our vice president of pharmacy explores the hard-to-predict impacts of drug price negotiations on consumers, plans and pharmaceutical companies.
![Pancreatic Cancer Screening, the New Guidelines, and Barriers to Care](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY0ZGFjYmZiZjE5ODcuanBnJnZlcnNpb249MDAwMCZzaWc9ZDU1MjdjZmMzMDAxNTllMTkyMDMwYzY1Y2QyOThlNzk%25253D&size=1&version=1708720386&sig=86cd0badd8d98ec50200a91151beb6d3&default=hubs%2Ftilebg-blogs.jpg)
Our CMO speaks with Urban Health Today about who should get screened, the role of primary care physicians in identifying at-risk individuals, and more.
![Genetic Testing in Cancer Care: Considerations for a Condition-Based Approach](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY0ZGFjYmZiZjE5ODcuanBnJnZlcnNpb249MDAwMCZzaWc9ZDU1MjdjZmMzMDAxNTllMTkyMDMwYzY1Y2QyOThlNzk%25253D&size=1&version=1708528911&sig=f81ebdc485b6372af3b86b8c8974cfa5&default=hubs%2Ftilebg-blogs.jpg)
Two Evolent experts discuss the benefits of genetic testing in oncology in American Journal of Managed Care.
![Evolent facilitates response to cancer drug shortages](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZTc0ZTIzOGRiOTcuanBlZyZ2ZXJzaW9uPTAwMDAmc2lnPTQ5N2M4NTNhOTFkMDNhMTEzYjBjNWVmNTk5MzNhN2Vk&size=1&version=1709658905&sig=f7c986de35271548aa86e57e253d0232&default=hubs%2Ftilebg-blogs.jpg)
Evolent takes a multifaceted approach to help providers navigate shortages of cisplatin, carboplatin and other anti-cancer drugs.
![The Make-or-Break Moment for Payers in Specialty Care](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY0ZGFjYjdkOTg5MGMuanBnJnZlcnNpb249MDAwMCZzaWc9MzBhZDdkNjE0Yzc2YmRiOTQxNzcxNDA4YThlNTEzYTU%25253D&size=1&version=1692625564&sig=60f227374a0389b19eb1437213b53378&default=hubs%2Ftilebg-blogs.jpg)
Our chief strategy officer speaks with Becker's about the largely untapped potential of value-based specialty care.
![Designing the High-Value Oncology Practice](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY0ZGFjYjljMTAwODEuanBnJnZlcnNpb249MDAwMCZzaWc9OGRhOGNkM2MyMjE2NDZkODY3MmFiMzYyNzYzNjBlYTM%25253D&size=1&version=1692625615&sig=83d576e37014cc007cb4ea37526cd40a&default=hubs%2Ftilebg-blogs.jpg)
Oncology Care Partners CEO Erich Mounce describes how his practices are purpose-built for value.
![Reducing Cancer Therapy’s Toll on the Heart](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY0ZmYyNjMzYmY2MGQuanBnJnZlcnNpb249MDAwMCZzaWc9OGNmOGUyY2Y2OWFkYzNkYjcyODE3ODA0Y2RiZjU0MDQ%25253D&size=1&version=1694454981&sig=19ecf719c608da732317d77b21d92a0d&default=hubs%2Ftilebg-blogs.jpg)
Evolent is leveraging our expertise in two key specialties to reduce cardiovascular damage related to cancer drugs.
![When Less is More in Radiation Oncology](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcyNTM1JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY0ZGJlMjkxYWU1ZDguanBnJnZlcnNpb249MDAwMCZzaWc9YTBkMDQzNTFiZDBiYWUyZjgxMzNlMDE4YzA3ODI3NmE%25253D&size=1&version=1692625653&sig=390004fe201fc07d662f067f2222cddd&default=hubs%2Ftilebg-blogs.jpg)
An Evolent program reduces unnecessary radiation treatments for breast cancer without compromising efficacy.